Monoclonal stool antigen test shows high accuracy for H. pylori detection in chronic atrophic gastritis patients.
This prospective primary care study enrolled 287 patients diagnosed with chronic atrophic gastritis (CAG). The primary objective was to assess the diagnostic accuracy of a monoclonal stool antigen test (SAT) against a reference standard that combined histology and urea breath test (UBT). Secondary outcomes included sensitivity, specificity, positive predictive value, overall accuracy, and agreement measured by kappa statistics.
The SAT demonstrated an area under the ROC curve of 0.858. Overall sensitivity was 75.9% and specificity was 96.1%. The study observed that performance metrics were positively correlated with the severity of gastric atrophy. Specifically, specificity in high-risk patients was 96.77% compared to 95.77% in low-risk patients. Positive predictive value was 95.24% in high-risk patients versus 93.48% in low-risk patients. Overall accuracy was 89.29% in high-risk patients versus 86.05% in low-risk patients.
Agreement between the SAT and the reference standard yielded a kappa of 0.72 overall. Agreement was 0.77 in high-risk patients and 0.69 in low-risk patients. No adverse events, serious adverse events, discontinuations, or tolerability data were reported in this study. The authors note that the test is a reliable non-invasive tool for detecting H. pylori in CAG, with performance improving in advanced atrophy populations.
Key takeaway: Consider using monoclonal SAT for H. pylori detection in high-risk CAG patients due to high specificity and strong consistency.